Piper Jaffray analyst Tyler Van Buren noted that Agios Pharmaceuticals’ Q3 earnings and Idhifa and Tibsovo results were in-line with his expectations, but the more important updates were the announcement of an sNDA filing by the end of January in frontline AML patients who aren’t candidates for current standard-of-care and the AGILE trial enrollment completion being accelerated a year following conversations with the FDA. The analyst, who believes the pull forward of the frontline AML filing “should be very well received,” recommends investors buy Agios shares at current levels and keeps an Overweight rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.